Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

被引：2

作者：

Sasaki, Koji ^{[1
]}

Kantarjian, Hagop M. ^{[1
]}

Samra, Bachar ^{[1
]}

Short, Nicholas J. ^{[2
]}

Khoury, Joseph D. ^{[3
]}

Kanagal-Shamanna, Rashmi ^{[3
]}

Konopleva, Marina Y. ^{[1
]}

Jain, Nitin ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Khouri, Rita ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Wierda, William G. ^{[1
]}

Tippett, Nicole ^{[1
]}

Garris, Rebecca ^{[1
]}

Jeanis, Victoria ^{[1
]}

Daver, Naval G. ^{[1
]}

Thompson, Philip A. ^{[1
]}

Yilmaz, Musa ^{[1
]}

Cortes, Jorge E. ^{[1
]}

O'Brien, Susan M. ^{[4
]}

Ravandi, Farhad ^{[1
]}

Jabbour, Elias ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[4] Univ Calif Irvine Hlth, Div Hematol Oncol, Dept Med, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128619

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Stock, Wendy
Martinelli, Giovanni
Stelljes, Matthias
DeAngelo, Daniel J.
Gokbuget, Nicola
Advani, Anjali S.
O'Brien, Susan Mary
Liedtke, Michaela
Merchant, Akil Abid
Cassaday, Ryan Daniel
Wang, Tao
Vandendries, Erik
Marks, David I.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Prognostic Significance of the Lost of a Major Molecular Response In Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph plus CML)
Valentin Garcia-Gutierrez, J.
Herrera, Pilar
Jimenez-Rolando, Marta
Tenorio, Maria
Calbacho, Maria
Jesus Blanchard, M.
Dolores Rey, Maria
Ramos, Paloma
Ramos, M. L.
Lopez, Javier
BLOOD, 2010, 116 (21) : 1408 - 1408
[43] EVALUATION OF CROSS-INTOLERANCE BETWEEN BOSUTINIB AND PRIOR TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIA
Cortes, J.
Lipton, J.
Kantarjian, H.
Khoury, H.
Hochhaus, A.
Baccarani, M.
Durrant, S.
Assouline, S.
Kim, D.
Bruemmendorf, T.
Leip, E.
Besson, N.
Turnbull, K.
Shapiro, M.
Gambacorti-Passerini, C.
HAEMATOLOGICA, 2013, 98 : 65 - 66
[44] A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL)
Zuo, Z.
Jones, D. M.
Thomas, D. A.
O'Brien, S.
Ravandi, F.
Kantarjian, H. M.
Medeiros, L. J.
Luthra, R.
Chen, S. S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[45] Successful Molecular Remission with Ponatinib in a 3-year-old Girl with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-Positive ALL)
Tanimura, Kazuki
Yamasaki, Kai
Okuhiro, Yuki
Hira, Kouta
Nitani, Chika
Okada, Keiko
Fujisaki, Hiroyuki
Matsumoto, Kana
Hara, Junichi
PEDIATRIC BLOOD & CANCER, 2018, 65 : S33 - S33
[46] Efficacy and Safety of Asciminib in Heavily Pretreated Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Sensitivity to Tyrosine Kinase Inhibitors (TKIs)
Hughes, Timothy
Mauro, Michael
Kim, Dong-Wook
Cortes, Jorge
Rea, Delphine
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel
Hochhaus, Andreas
Goh, Yeow-Tee
le Coutre, Philipp
Lang, Fabian
Cacciatore, Silvia
Aimone, Paola
Stenson, Laura
Polydoros, Fotis
Talpaz, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S235 - S235
[47] Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
Sasaki, Koji
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Cortes, Jorge E.
Pemmaraju, Naveen
Kadia, Tapan M.
Short, Nicholas James
Issa, Ghayas C.
Garris, Rebecca S.
Jeanis, Vicky
Moore, H. Gal
Garcia-Manero, Guillermo
Borthakur, Gautam
Wierda, William G.
Gachimova, Evguenia
O'Brien, Susan Mary
Jabbour, Elias
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[48] Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
Ravandi, Farhad
Jorgensen, Jeffrey L.
Thomas, Deborah A.
O'Brien, Susan
Garris, Rebecca
Faderl, Stefan
Huang, Xuelin
Wen, Sijin
Burger, Jan A.
Ferrajoli, Alessandra
Kebriaei, Partow
Champlin, Richard E.
Estrov, Zeev
Challagundla, Pramoda
Wang, Sa A.
Luthra, Rajyalakshmi
Cortes, Jorge E.
Kantarjian, Hagop M.
BLOOD, 2013, 122 (07) : 1214 - 1221
[49] A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
Short, Nicholas James
Jabbour, Elias
Jain, Nitin
Macaron, Walid
Huang, Xuelin
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Daver, Naval Guastad
Haddad, Fadi
Zoghbi, Marianne
Nasnas, Cedric Christophe
Nasr, Lewis Fady
Mayor, Ejiroghene
Deen, Wuliamatu
Thankachan, Jennifer
Loiselle, Christopher
Garris, Rebecca
Konopleva, Marina
Ravandi, Farhad
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Further improvement of outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) treated with imatinib-combined chemotherapy
Ohno, R.
Yanada, M.
ANNALS OF HEMATOLOGY, 2008, 87 : S73 - S75

← 1 2 3 4 5 →